Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4006896 single-ascending-dose and multiple-dose study in healthy participants and Parkinson's disease
jRCT2031250223Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1 trial of LY4006896 in Parkinson's disease (PD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with one or more serious adverse events (SAEs) - Part A, Number of participants with one or more treatment-emergent adverse events (TEAEs) - Part A and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
LY4006896
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2031250223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250223.